[CA] Etude comprative de coût entre immunoglogulines et plasmaphérèses

Rubrique ouverte à tous en lecture seule.
POUR ACCEDER AUX NOMBREUX AUTRES FORUMS IL EST NECESSAIRE DE S'INSCRIRE (fonction M'enregistrer en haut à droite de l'écran).
Répondre
Avatar de l’utilisateur

Auteur du sujet
Pboulanger
Administrateur
Administrateur
Messages : 4694
Inscription : 02 févr. 2010 18:41
Localisation : La Chapelle en Serval F-60520
    Windows 8.1 Firefox
Genre :
Résidence : France
Zodiaque : Lion
Âge : 60
Contact :

[CA] Etude comprative de coût entre immunoglogulines et plasmaphérèses

Message par Pboulanger » 27 nov. 2015 09:19

:hi:

Lu sur Willey online http://onlinelibrary.wiley.com/doi/10.1 ... avedsearch
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Image
Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis
Julio C. Furlan MD, FRCPC1,*, David Barth MD, FRCPC2, Carolina Barnett MD3 andVera Bril MD, FRCPC3
Article first published online: 26 NOV 2015
DOI: 10.1002/mus.24960


ABSTRACT

Introduction
Myasthenia gravis (MG) exacerbations may be treated with intravenous immunoglobulin (IVIg) or plasma exchange (PLEX), which have equivalent effectiveness. This cost-minimization analysis compared IVIg with PLEX for treatment of patients with MG exacerbation.

Methods
We combined the Ontario-based health cost data with clinical data from a randomized clinical trial. Analyses were undertaken from the perspective of a public healthcare insurer and from the perspective of a tertiary university hospital payer.

Results
PLEX was less costly than IVIg among patients with a body mass index (BMI) > 15.7 kg/m2, from the perspective of the public healthcare insurer (P < 0.0001). However, PLEX was more costly than IVIg from the perspective of the hospital payer when the costs of blood products were excluded (P < 0.0001).

Conclusions
PLEX can be considered a short-term cost-minimizing therapy when compared with IVIg for treatment of MG exacerbation among patients with BMI >15.7 kg/m2, from the perspective of a public healthcare insurer.

Muscle Nerve, 2015
Amicalement,
Image

Répondre

Revenir vers « Informations »

Qui est en ligne ?

Utilisateurs parcourant ce forum : Aucun utilisateur inscrit et 1 invité